Neurocrine Biosciences (NBIX) EBT Margin (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EBT Margin for 16 consecutive years, with 16.91% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT Margin fell 629.0% year-over-year to 16.91%; the trailing twelve-month figure through Jun 2026 stood at 27.87% (up 687.0% YoY), and the FY2025 full-year result was 24.66%, up 403.0% from the prior year.
• EBT Margin slipped to 16.91% in Q2 2026 per NBIX's latest filing, from 30.3% in the prior quarter.
• Across five years, EBT Margin topped out at 38.47% in Q4 2023 and bottomed at 24.57% in Q1 2023.
• Historically, EBT Margin has averaged 18.77% across 5 years, with a median of 24.22% in 2022.
• The sharpest annual moves came in 2022 and 2023: EBT Margin soared 3304 bps in 2022, then sank 3146 bps in 2023.
• Over 5 years, EBT Margin stood at 28.62% in 2022, then surged by 34 bps to 38.47% in 2023, then sank by 33 bps to 25.9% in 2024, then rose by 15 bps to 29.72% in 2025, then tumbled by 43 bps to 16.91% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 16.91%, 30.3%, and 29.72% for Q2 2026, Q1 2026, and Q4 2025 respectively.